June 29, 2018

Major Academic Health System Taps Glytec for Insulin Management Technology

Duke University Health System has selected Glytec’s eGlycemic Management System® to elevate the quality and safety of care for patients with diabetes and others who require insulin therapy.

With national statistics indicating that one of every three hospitalized patients requires insulin therapy during their stay, administering the right dose at the right time in accordance with best practices is integral to safe, effective care and speedy recovery. By implementing Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) for personalized medication optimization, Duke Regional Hospital of Durham, North Carolina is equipping its staff with a proven and highly efficient means to individualize and standardize insulin therapy. Among the key benefits of eGMS® are helping prevent hypoglycemia and hyperglycemia while also rapidly achieving and maintaining glycemic targets and reducing length of stay.

May 1, 2018

University of New Mexico Hospital to Bolster Patient Safety and Diabetes Care in Partnership with Glytec

New Mexico’s only academic medical center will soon implement Glytec’s evidence-based eGlycemic Management System® for best practices in insulin therapy management.

University of New Mexico Hospital, already a distinguished leader in diabetes care, is partnering with Glytec to achieve the highest levels of quality and safety for hospitalized patients who require insulin therapy. Using Glytec’s eGlycemic Management System®, the Albuquerque-based academic medical center will not only introduce greater standardization and systemization around best practices in glycemic management, but will aim to realize the very significant goal of eliminating severe hypoglycemia.

March 21, 2018

Glytec Announces Appointment of Ed Furlong as Chief Operating Officer

Furlong joins the company during a period of extraordinary growth and will assume a key leadership role in scaling commercial operations to meet evolving customer needs.

Glytec, the pioneer of personalized digital therapeutics, is pleased to announce the appointment of Ed Furlong as Chief Operating Officer. “We are thrilled to welcome Ed Furlong to our executive team,” says Glytec’s President and CEO, Bob Leonard. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”

March 20, 2018

Piedmont Healthcare Expands Use of Glytec’s Software for Insulin Therapy Management

Atlanta-based Piedmont Healthcare will implement Glytec’s eGlycemic Management System® across all acute care facilities.

Standardizing and personalizing insulin therapy management for hospitalized patients is a goal Piedmont Healthcare is poised to achieve through expanded use of Glytec’s eGlycemic Management System®, or eGMS®. The not-for-profit healthcare system currently uses eGMS® at Piedmont Atlanta Hospital, Piedmont Newnan Hospital and Piedmont Athens Regional Medical Center. Based on a new agreement, Piedmont Healthcare will implement eGMS® at Piedmont Henry Hospital, Piedmont Fayette Hospital, Piedmont Newton Hospital and Piedmont Mountainside Hospital.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

December 5, 2017

Chesapeake Regional Healthcare will Implement Glytec’s Software to Bolster High-Reliability Care

Glytec’s eGlycemic Management System® will ensure clinicians have ready access to evidence-based decision support for personalized insulin therapy management.

Fostering a culture of patient safety is integral to the care Chesapeake Regional Healthcare delivers, and a new partnership with Glytec will enable best practices in glycemic management across all inpatient service lines. Glytec’s eGlycemic Management System® will support the optimization of intravenous and subcutaneous insulin therapy during hospitalization, and will provide evidence-based guidance on transitions in insulin therapy from hospital to home.

November 27, 2017

Electronic Glycemic Management Improves Outcomes for Diabetics

According to new data from a quality improvement study, patients with diabetes experienced no diabetes-related readmissions, urgent care visits, or emergency department visits within 30 days of hospital discharge when their healthcare providers used Glytec’s eGlycemic Management System to guide insulin regimens prescribed at discharge.

Researchers at Eastern Virginia Medical School conducted the study and presented their findings earlier this month at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.

November 8, 2017

Study Observed Improvements in Transitions of Care Using Hospital-to-Home Diabetes Therapy Management Software from Glytec

New data presented at the 17th Annual Diabetes Technology Meeting observed no diabetes-related readmissions, urgent care visits or emergency department visits within 30 days of hospital discharge when using Glytec’s software.

A prospective quality improvement study led by Eastern Virginia Medical School and presented at the 17th Annual Diabetes Technology Meeting highlights the importance of properly managing transitions of care for patients with diabetes. The study observed that when providers used the Hospital-to-Home (H2H®) module of Glytec’s eGlycemic Management System® to guide insulin regimens prescribed at discharge, patients had no diabetes-related readmissions, urgent care visits or emergency department visits within the first 30 days.

October 17, 2017

Adventist Health System Partners With Glytec to Enhance Diabetes Care

The health system will utilize Glytec’s eGlycemic Management System® at 39 of its acute care facilities.

More than a quarter of all hospitalized patients in the U.S. have diabetes, and typically, these patients stay longer, experience more infections and have higher readmission rates.* Recognizing the unique challenges of caring for patients with diabetes, Adventist Health System, one of the largest faith-based health systems in the U.S., has partnered with Glytec, a leader in diabetes therapy management software and medication optimization, to implement the eGlycemic Management System® (eGMS®) at 39 of its acute care facilities.

September 23, 2017

Glytec Moves Beyond Clinical Results to Touting Savings

The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.

This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.

August 18, 2017

Presentation at AADE Conference Showcases Value of Diabetes Decision Support Solutions

Diabetes educators learned how Glytec’s software and other data-driven technologies help overcome key challenges of insulin management.

A presentation on diabetes decision support solutions at this year’s American Association of Diabetes Educators (AADE) conference showcased how use of Glytec’s therapy management software in conjunction with connected device systems is breaking down barriers to effective and timely insulin management and, as a result, reducing the risks and costs of diabetes for providers, payers and patients alike.

August 16, 2017

Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software

The company’s eGlycemic Management System® featuring Glucommander™ has the broadest indications for use of any decision support solution for insulin titration.

The pioneer of diabetes therapy management software, Glytec announces its fourth FDA clearance, adding a broad array of capabilities to Glucommander™, the core of its patented eGlycemic Management System®. As the first company to receive FDA clearance for an insulin titration decision support solution — a milestone that occurred in 2006, the year it was founded — Glytec continues to lead this critically important and evolving category of technology-enabled medication optimization.

June 21, 2017

With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.

June 20, 2017

Raymie McFarland Discusses Findings From Glytec’s Basal-Bolus Insulin Study

Glytec’s eGlycemic Management System (eGMS) helped the Kaweah Delta hospital shift its standard of care to basal-bolus insulin, explained Raymie McFarland, vice president of Quality Initiatives at Glytec. Basal-bolus is considered best practice and is safer for patients, but many hospitals have not adopted it due to its difficulty. Glytec hopes its eGMS can change that.

The poster that’s being presented is a case study looking at a 500-plus bed hospital in the San Joaquin Valley of California. It’s a facility named Kaweah Delta Regional Medical Center. Kaweah Delta is a very interesting case in that they did not have expertise from an endocrinology standpoint either in or outside the hospital or the health system facilities.

June 7, 2017

Case Studies Presented at Diabetes Technology Society Conference Highlight Millions in Hospital Cost Savings with Improved Glucose Control

One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.

May 8, 2017

Computer-Guided Insulin Titration Helps Hospitals Meet Basal Bolus Standard, Study Finds

An analysis of an electronic glucose management system developed by Glytec, which helps nurses safely manage basal bolus insulin dosing in the hospital, was presented at the recent meeting of the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, held in Austin, Texas.

The movement toward quality ratings — and an increased emphasis on preventing readmissions — demanded solutions that help hospitals achieve the standard, which ADA clarified in January 2017 to state that basal bolus insulin was the preferred treatment for noncritically ill patients, and that, “Prolonged sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged.”

Improving Quality of Care with Electronic Glycemic Management System

At AACE 2017, Jagdeesh Ullal, MD, MS, Eastern Virginia Medical School discussed data from his team’s study that assessed the efficacy of an electronic glycemic management system (eGlycemic Management System) in controlling blood sugars in the hospital setting. 

The study was conducted at Wake Forest, but the data was collected across 9 hospitals including about 1600 patients. Ullal explained that patients with diabetes come to the hospital often have high levels of blood sugar. “In our study, the patients, on average, had blood sugar levels of 200 when they came in, and over the course of their stay, their blood sugars were brought back to the normal range (140-180). We were able to achieve that with the eGlycemic Management System software that has also been proven in various other aspects of glucose management in the hospital.”

May 4, 2017

Study Shows Computer-Guided Insulin Titration Enables Basal Bolus Standard of Care

New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System® eliminates barriers to adoption of basal bolus insulin and produces superior patient outcomes.

A multi-center post-hoc analysis presented at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific & Clinical Congress by Drs. Jagdeesh Ullal and Joseph Aloi demonstrates that Glytec’s eGlycemic Management System® (eGMS®) enables hospitals to achieve the basal bolus standard of care for subcutaneous insulin therapy with extraordinary efficiency and superior patient outcomes. The new research study, entitled ‘AUTO Study, AUtomatic Titration tO Target: Subcutaneous Basal Bolus Insulin Management Using eGMS in the Non-ICU Setting,’ observed a 19% reduction in average daily blood glucose between admission and discharge — with 0.00% severe hypoglycemia < 40 mg/dL -- while achieving the prescribed target blood glucose of 140-180 mg/dL at all mealtime and bedtime intervals.

April 26, 2017

Research Study from Emory University Observes $3,654 Per Patient Cost Savings for CABG Surgery

Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.

A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.